Search Results
Aug 04, 2026, 03:00 ET Haut.AI Launches AI-Powered Clinical Studies Software for Large-Scale Skin Studies Across Clinic, Hybrid, and At-Home Environments
TruDiagnostic. "Haut.AI's Clinical Studies Software gave us standardized, image-derived measures of facial aging traits that we could pair directly with our DNA methylation data. That combination let us treat visible aging as a quantitative trait alongside our biological measurements, instead of relying on subjective
More news about: Haut.AI
Aug 03, 2026, 16:10 ET Alexandria Real Estate Equities, Inc. Reports 2Q26 and 1H26 Net (Loss) Income per Share - Diluted of $(0.43) and $1.68, respectively, and 2Q26 and 1H26 FFO per Share - Diluted, as Adjusted, of $1.73 and $3.46, respectively
Alexandria®, Lighthouse Design® logo, Building the Future of Life-Changing Innovation®, That's What's in Our DNA®, Megacampus™, At the Vanguard and Heart of the Life Science Ecosystem™, Alexandria Center®, Alexandria Technology Square®,
More news about: Alexandria Real Estate Equities, Inc.
Aug 03, 2026, 12:00 ET Human Longevity Makes Clinical-Grade Whole Genome Sequencing Available to All for $599
Genomics for All, a clinical-grade whole genome sequencing product priced at $599. The offering sequences all 6.4 billion base pairs of an individual's DNA and delivers AI-interpreted results through the HLI app, with no clinic visit required.
More news about: Human Longevity, Inc.
Aug 03, 2026, 10:01 ET Green Science Alliance Developed Carbon Quantum Dot type Pest Repellent from Organic Biomass Waste (Wood Waste, Plant Waste, Food Waste)
effect against insects. He suggests some reasons as followings. Ultra-small quantum dots can pass through insect cells and nuclear membranes to damage DNA, quantum dots emit light at wavelengths that insects dislike, or quantum dots also have photocatalytic properties, meaning that when exposed to sunlight,
More news about: Green Science Alliance Co., Ltd.
Aug 03, 2026, 09:00 ET STANLEY® Launches ALL BUILD. NO BULL., a Bold New Campaign Championing the Pros Who Keep It Real
Europe, Australia and New Zealand starting in August. All Build from Day One The all-work mentality has been part of STANLEY's DNA from the start. When the brand was founded in 1843, Founder Frederick Stanley saw the need for a brand that made tools shaped by the work, and workers
More news about: STANLEY
Aug 03, 2026, 08:00 ET FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection
candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that
More news about: Acurx Pharmaceuticals, Inc.
Aug 02, 2026, 14:34 ET HIZENERGY sa pridáva ku globálnej špičke - zaradenie do zoznamu BloombergNEF 1. úrovne
HEFEI, Čína, 2. augusta 2026 /PRNewswire/ – Dňa 31. júla 2026 zverejnil BloombergNEF (BNEF), popredný svetový inštitút pre výskum v oblasti energetiky, svoj zoznam výrobcov úložísk energie 1. úrovne na tretí štvrťrok 2026.
More news about: HIZENERGY
Jul 31, 2026, 13:31 ET Nabsys and Indiana University Collaborate to Advance Electronic Genome Mapping Applications in Hematologic Malignancies
determine how it may enhance existing cytogenetic research workflows.The OhmX™ Platform uses proprietary electronic detection to analyze ultra-long DNA molecules. By replacing complex and expensive optical systems with precision electronics, EGM enables a compact, cost-effective platform capable of delivering
More news about: Nabsys
Jul 31, 2026, 10:30 ET Animal Genetics Market worth $9.37 billion by 2031 - Exclusive Report by MarketsandMarkets™
and precision breeding, diagnostic centers are expanding their molecular testing capabilities using technologies such as PCR, SNP genotyping, NGS, and DNA sequencing to deliver accurate and high-throughput genetic analyses. Rising awareness of genetic disease prevention, growing outsourcing of genetic testing
More news about: MarketsandMarkets
Jul 31, 2026, 08:30 ET PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
subsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer
More news about: PAVmed Inc.
Jul 30, 2026, 16:05 ET Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in
More news about: Illumina, Inc.
Jul 30, 2026, 10:35 ET Peer-Reviewed Study Validates First Blood Test for Early-Stage Breast Cancer Detection
decades, liquid biopsies have leaned on DNA-based blood tests — an approach that has struggled for breast cancer for a simple biological reason: early breast tumors shed only about a tenth of the DNA compared to other cancers, including colorectal. That is why DNA-based multi-cancer tests have shown low
More news about: Astrin Biosciences
Jul 30, 2026, 09:00 ET Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast
diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to
More news about: Co-Diagnostics
Jul 30, 2026, 08:30 ET Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its
More news about: Lucid Diagnostics
Jul 30, 2026, 05:09 ET NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment.
More news about: Kelun-Biotech
Jul 29, 2026, 20:53 ET INOVIO Announces Pricing of $20.0 Million Public Offering
biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting
More news about: Inovio Pharmaceuticals, Inc.
Jul 29, 2026, 16:01 ET INOVIO Announces Proposed Public Offering
biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting
More news about: Inovio Pharmaceuticals, Inc.
Jul 29, 2026, 13:14 ET GMP Biologics Market to Reach US$98.2 Bn by 2033 Accelerates with Biopharmaceutical Innovation - Persistence Market Research
2033Europe DNA Encoded Library Market by Offering (Services, Products), Application (Oncology, Infectious Diseases, Metabolic Disorders, Cardiovascular Diseases,
More news about: Persistence Market Research Pvt. Ltd.
Jul 29, 2026, 11:00 ET ABSOLUTE RECOMP IS BUILDING THE FITNESS CATEGORY THE INDUSTRY FORGOT TO BUILD
am maniacally focused on an unparalleled AR experience and ensuring we stay true to our committed core demographic. This standard is baked into our DNA."— Tim Kurtz, Partner, President and Chief Experience Officer, Absolute RecompAbout Absolute RecompAbsolute
More news about: Absolute Recomp
Jul 29, 2026, 09:04 ET InsideTracker Unveils Source-Agnostic Blood Data Processing Across Nearly 120 Biomarkers
enterprises. Backed by over a decade of peer-reviewed science, the company's Terra™ platform provides a flexible intelligence layer that analyzes blood, DNA, fitness tracking, and lifestyle habits. By translating complex biological data into precise, 1:1 recommendations across nutrition, supplements, exercise,
More news about: InsideTracker
Jul 29, 2026, 08:30 ET Improve Biologic Modalities Manufacturing for mAb Readiness, Upcoming Webinar Hosted by Xtalks
development and manufacturing organization (CDMO) providing integrated process development, analytical development, and CGMP biologics manufacturing from DNA to IND to commercial supply. With you, every molecule of the way.To learn more about Avid Bioservices, visit
More news about: Xtalks
Jul 29, 2026, 03:00 ET AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should occur before and during therapy. If hepatitis B virus DNA is detected, a liver specialist should be consulted.VaccinationThe use of live, attenuated vaccines during or immediately prior
More news about: AbbVie
Jul 29, 2026, 03:00 ET AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should occur before and during therapy. If hepatitis B virus DNA is detected, a liver specialist should be consulted.VaccinationThe use of live, attenuated vaccines during or immediately prior
More news about: AbbVie
Jul 28, 2026, 10:56 ET Kennedy Funding Expands International Lending Footprint with $1.26 Million Land Loan in Cartagena, Colombia
needs, giving borrowers flexible capital solutions tailored to each project's objectives."International lending has been part of Kennedy Funding's DNA for decades," said Kevin Wolfer, CEO of Kennedy Funding. "Our experience, creativity, and willingness to think beyond traditional lending boundaries
More news about: Kennedy Funding
Jul 28, 2026, 10:10 ET VIDA SHOES INTERNATIONAL, INC. ACQUIRES DONALD PLINER®
International, Inc. "Our goal is to provide additional resources, infrastructure and expertise that will accelerate growth while remaining true to the brand's DNA. We look forward to working closely together and building on the strong foundation already in place.""Having led Donald Pliner for the past six
More news about: Vida Shoes International